Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[(5R,14R)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1~7,11~]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule inhibitor designed to target beta-secretase 1 (BACE1). BACE1 is an aspartyl protease involved in the cleavage of amyloid precursor protein (APP) to produce beta amyloid peptides implicated in Alzheimer's disease pathology[2][5]. The compound has been studied structurally as a ligand bound to human BACE1 and is classified among experimental drugs with no current approved therapeutic use[2][5]. Its primary mechanism of action is inhibition of BACE1 activity.
- Other names
- N-((5R,14R)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo(15.3.1.1?,11)docosa‑1(21),7,9,11(22),17,19‑hexaen‑19‑yl)‑N-methylmethanesulfonamideN-{5-amino–5,14-dimethyl–4–oxo–3–oxa–18–azatricyclo[15.3.1.1^{7,11}]docosa−1(21),7(22),8,10,17,19-hexaen−19−yl}−N-methylmethanesulfonamide
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)
Beyond the preview
Go deeper on N-[(5R,14R)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1~7,11~]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[(5R,14R)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1~7,11~]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide.